BeStock  

Bio-Rad Laboratories BIO

US equityMarket cap rank #1437Medical Devices
$358.90 −$8.60 (-2.34%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $358.90 0.00%
Open$364.34
Prev close$367.50
Day range$353.31 – $369.44
Volume182.3K
Market cap$9.65B
P/E (TTM)9.5
Dividend yield–

BIO Stock News

Headlines matching Bio-Rad Laboratories or the BIO ticker, most recent first.

  • Lake Street Maintains TELA Bio(TELA.US) With Buy Rating, Maintains Target Price $2Market news · 30 Sep 2026 · Direct mention
  • Huaheng Bio: Implementation and Assessment Management Measures for the 2026 Restricted Stock Incentive Plan of Anhui Huaheng Biotechnology Co., Ltd.SZSI · 30 Sep 2026 · Direct mention
  • Citi Initiates Nuvation Bio(NUVB.US) With Buy Rating, Announces Target Price $12Market news · 30 Sep 2026 · Direct mention
  • L&C BIO Co: Report on Status of Specific Securities, Etc. Owned by Executives and Major ShareholdersOPENDART · 30 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $34Market news · 30 Sep 2026 · Direct mention
  • Clear Street Initiates Q32 Bio(QTTB.US) With Buy Rating, Announces Target Price $38Market news · 29 Sep 2026 · Direct mention
  • Wedbush Maintains Adicet Bio(ACET.US) With Buy Rating, Raises Target Price to $28 PositiveMarket news · 29 Sep 2026 · Direct mention
  • CCORF Maintains Adicet Bio(ACET.US) With Buy Rating, Maintains Target Price $18Market news · 29 Sep 2026 · Direct mention
  • Bio-Rad Laboratories (BIO) Receives a Buy From RBC CapitalTipRanks · 28 Sep 2026 · Direct mention
  • RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Maintains Target Price $390Market news · 28 Sep 2026 · Direct mention
  • RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $390 PositiveMarket news · 7 Aug 2026 · Direct mention
  • Bio‐Rad Laboratories Balances Recovery And Headwinds In Q2TipRanks · 18 Aug 2026 · Direct mention
  • Bio-Rad Laboratories | 8-K: Bio-Rad Reports Third -Quarter 2026 Financial ResultsSEC · 5 Nov 2026 · Direct mention
  • RBC Capital Maintains Bio-Rad Laboratories(BIO.US) With Buy Rating, Raises Target Price to $440 PositiveMarket news · 5 Nov 2026 · Direct mention
  • Bio-Rad Laboratories Affirms FY2026 Sales Guidance of $2.506B-$2.596B Vs $2.588B EstBenzinga · 5 Nov 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on BIO.

Sign in to join the discussion.

Scroll to Top